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Background: Expression of integrin α3β1 is associated with tumor progression, metastasis, and poor prognosis in
several cancers, including breast cancer. Moreover, preclinical studies have revealed important pro-tumorigenic and
pro-metastatic functions for this integrin, including tumor growth, survival, invasion, and paracrine induction of
angiogenesis. Our previously published work in a preclinical breast cancer model showed that integrin α3β1
promotes expression of cyclooxygenase-2 (COX2/PTGS2), a known driver of breast cancer progression. However, the
clinical significance of this regulation was unknown. The objective of the current study was to assess the clinical
relevance of the relationship between integrin α3β1 and COX2 by testing for their correlated expression among
various forms of human breast cancer.
Methods: Immunohistochemistry was performed to assess co-expression of α3 and COX2 in specimens of human
invasive ductal carcinoma (IDC), either on a commercial tissue microarray (n = 59 samples) or obtained from Albany
Medical Center archives (n = 68 samples). Immunostaining intensity for the integrin α3 subunit or COX2 was scored,
and Spearman’s rank correlation coefficient analysis was performed to assess their co-expression across and within
different tumor subtypes or clinicopathologic criteria.
Results: Although expression of integrin α3 or COX2 varied among clinical IDC samples, a statistically significant,
positive correlation was detected between α3 and COX2 in both tissue microarrays (rs = 0.49, p < 0.001, n = 59) and
archived samples (rs = 0.59, p < 0.0001, n = 68). In both sample sets, this correlation was independent of hormone
receptor status, histological grade, or disease stage.
Conclusions: COX2 and α3 are correlated in IDC independently of hormone receptor status or other
clinicopathologic features, supporting the hypothesis that integrin α3β1 is a determinant of COX2 expression in
human breast cancer. These results support the clinical relevance of α3β1-dependent COX2 gene expression that
we reported previously in breast cancer cells. The findings also suggest that COX2-positive breast carcinomas of
various subtypes might be vulnerable to therapeutic strategies that target α3β1, and that α3 expression might serve
as an independent prognostic biomarker.
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The most significant cause of mortality in women with
breast cancer is metastasis of the primary tumor, and the
identification of therapeutic targets to effectively inhibit
malignant progression and metastatic spread remains a
barrier to the treatment of breast cancer in the clinic.
Integrins are the major cell surface receptors for adhesion
to the extracellular matrix (ECM), and they are appealing
targets for anti-cancer therapies. Indeed, integrins function
as bidirectional signaling receptors that regulate both cel-
lular responses to cues from the tissue microenvironment
and cell-mediated changes to the microenvironment, and
integrin signaling in tumor cells is known to be critically
important for promoting malignant growth and metastasis
[1-5]. In addition, as cell surface receptors integrins are
relatively accessible to inhibitory agents, and several pep-
tide antagonists and humanized monoclonal antibodies
that target integrins are in clinical development [2].
All members of the integrin family are transmembrane
glycoproteins consisting of an α and a β subunit, where
18 α subunits and 8 β subunits can heterodimerize in
different combinations to form 24 distinct integrins with
different ligand-binding specificities [3]. The laminin-
binding integrin α3β1 is widely expressed in epithelial
tissues, including the mammary epithelium, the epidermis,
and the kidney glomeruli, where it is important for normal
tissue development or function [6-9]. In the normal mam-
mary gland, α3β1 is expressed in both epithelial cells and
endothelial cells. Although α3β1 is not required for gross
development and differentiation of the mammary gland,
genetic deletion of α3 from myoepithelial cells in the
lactating mammary gland leads to contractile defects that
reduce milk secretion [9,10]. A number of studies have
shown that α3β1 promotes tumor growth, invasion, and/
or metastasis of breast cancer or other carcinoma cells
[11-15]. In addition, two major ECM ligands for α3β1,
laminin-332 and laminin-511, are often over-expressed in
breast and other carcinomas, and both of these laminins
have been linked to tumor invasion and metastasis
[16-20]. Indeed, one group’s recent analysis of the Breast
Invasive Carcinoma TCGA database revealed a link be-
tween decreased patient survival and co-upregulation of
the genes encoding the integrin α3 subunit (ITGA3) and
the laminin α5 chain (LAMA5) [15].
Previous studies from our group and others using the
triple-negative, aggressive human breast cancer cell line,
MDA-MB-231, have shown that integrin α3β1 promotes
invasion in vitro and tumor growth in vivo [11,12]. In
addition, shRNA-mediated suppression of α3β1 in these
cells caused reduced expression of several pro-tumorigenic/
pro-invasive genes, including cyclooxygenase-2 (COX2/
PTGS2) [11]. Furthermore, COX2 was required for some
α3β1-mediated cell functions that likely contribute to ma-
lignant tumor growth, including invasive potential andpro-angiogenic crosstalk to endothelial cells [11]. These
findings have potential clinical significance, as COX2
is a known mediator of breast cancer progression and
metastasis that has been an important clinical target of in-
hibitory therapies [21-23]. Indeed, both non-steroidal anti-
inflammatory drugs (NSAIDs) and agents that selectively
target COX2 (i.e., celecoxib, rofecoxib, valdecoxib) have
been developed [24-26]. However, some COX2 inhibitors
produce serious side effects such as gastrointestinal,
cardiovascular, liver and kidney complications [27-29],
resulting in their voluntary withdrawal from the mar-
ket in some cases [30,31]. Therefore, exploiting α3β1 as a
therapeutic target to down-regulate COX2 gene expres-
sion might circumvent certain side effects that have been
associated with direct inhibitors of COX2. However, a
potential link between α3β1 and COX2 in clinical samples
of human breast cancer has not been investigated.
In the current study, we used an immunohistological
approach to compare expression of α3 integrin (ITGA3)
and COX2 (PTGS2) among clinical samples of human
invasive ductal carcinoma (IDC), and to determine
whether there is a correlative relationship between them.
Our findings revealed that while the expression of α3β1
varies among clinical samples of IDC, α3β1 showed a
statistically significant, positive correlation with COX2
expression. This correlation was detected among tumors
of different hormone receptor status, suggesting that α3
expression might serve as an independent prognostic
indicator. Together with our earlier findings that α3β1
promotes COX2 expression in breast cancer cells [11],
our current data suggest that α3β1 expression may be a
determinant of COX2 expression in human breast can-
cer, and that COX2-positive carcinomas of various sub-




Commercially purchased tissue microarrays (TMAs) in-
cluded 59 samples of invasive ductal carcinoma (IDC)
(Pantomics, Inc., San Francisco, CA, USA; catalog num-
ber BRC711), and 12 samples that included normal
breast, hyperplasia, IDC, apocrine carcinoma and inva-
sive lobular carcinoma (US Biomax, Inc., Rockville, MD,
USA; catalog number T087). In addition, a total of 68
formalin-fixed, paraffin embedded samples of IDC were
obtained as archival biopsy material without patient
identifiers from the Department of Pathology at Albany
Medical Center. Accompanying pathology reports for
the latter samples provided information regarding sur-
vival status, diagnosis, grade, stage, metastasis of carcin-
oma, lymph node status and hormone receptor status of
patients. This study was approved by the Institutional
Review Board of Albany Medical Center.
Figure 1 (See legend on next page.)
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Figure 1 Expression of integrin α3 and COX2 in human IDC (Pantomics TMA). (A) Images show representative scoring intensities following
immunostaining of adjacent regions from the same tumor with the indicated antibodies (range of 0-3; see Methods). Tissues were also stained
with DAB as chromogen, and counter-stained with hematoxylin. The pre-immune serum (first column) was used to determine background
staining for each set. Scale bar, 25 μM. (B) Table depicts co-distribution of like scores for α3 and COX2. Blue shading highlights a positive correlation
for expression of α3 and COX2 among the 59 IDC samples. Spearman’s rank correlation coefficient (rs = 0.49; p < 0.001) indicates a significant correlation
between α3 and COX2 expression (see Table 2).
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Immunohistology was performed as previously described
[32]. Briefly, formalin-fixed paraffin embedded tissues
were baked at 55°C for 30 min, then deparaffinized in
xylene for 10 minutes and hydrated in an ethanol gradi-
ent (100%, 95%, 80%, 70%, distilled water). Tissues were
steamed for 30 min in antigen-retrieval solution (Biogenex
Laboratories, Fremont, CA, USA), then cooled and
washed with 0.1% PBS-BSA solution. Tissue sections were
then treated with 3% hydrogen peroxide for 20 minutes,
followed by blocking in normal horse serum (Vectastain
Elite Kit, Vector Laboratories, Burlingame, CA, USA) for
30 min at room temperature. Tissues were then incubated
with rabbit pre-immune serum, or with rabbit poly-
clonal antiserum against the integrin α3 subunit [33]
(1:500 dilution, 1 hr), COX2 (1:200 dilution, 1 hr; Cell
Signaling, Danvers, MA, USA) or von-Willebrand Factor
(vWF, 1:400 dilution, 30 min; DAKO, Carpenteria, CA) at
room temperature, followed by incubation with secondary
antibody (Vectastain Elite Kit) for 30 min, then avidin-
biotin complex (ABC) for 30 min, according to the manu-
facturer’s instructions. Specificity of the anti-α3 serum has
been demonstrated in previous studies [34,35], and was
confirmed under specific conditions of tissue fixation and
antigen-retrieval used in the current study by immuno-
staining of paraffin-embedded sections prepared from
neonatal skin of wildtype or α3-knockout mice (data not
shown). Sections were stained with 3,3′-diaminobenzidine
(DAB; #550880; BD Biosciences, Franklin Lakes, NJ, USA),
counterstained with hematoxylin for 20 sec, dehydrated in
an ethanol gradient (70%, 80%, 95%, 100%), then immersed
in xylene. Sections were mounted using Permount (Sigma,
St. Louis, MO, USA) and photographed at 100× magni-
fication using a Nanozoomer (Hamamatsu, Bridgewater,
NJ, USA).
Statistical analysis
Immunohistological staining of breast tissue microar-
rays for α3 or COX2 was scored blindly by a pathologist
using the following criteria: 0 = background, 1 =weakly posi-
tive, 2 =moderately positive, 3 = strongly positive. Scores for
α3 and COX2 were tabulated, and chi-square tests for trend
analyses were performed to analyze the relationship be-
tween α3 expression and pathologic diagnostic criteria.
Spearman’s rank correlation coefficient analyses were per-
formed to test for a statistically significant positive ornegative correlation between α3β1 and COX2 expression
across breast cancer subtypes or diagnostic criteria using
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA,
USA). A p-value of <0.05 was considered statistically
significant.
To assess blood vessel density, tumor sections were
stained with anti-vWF. Within the region of interest
(ROI), the area that stained positive for vWF above a
threshold that was set using background staining levels,
as determined using IPLab (Scanalytics, Inc., Milwaukee,
WI), was averaged between two fields as we described
previously [35]. Blood vessel area in relation to the α3
score was analyzed by one-way ANOVA using GraphPad
Prism.
Results
Analysis of integrin α3β1 expression in clinical breast
tumor tissues
To assess α3β1 expression among breast cancer samples,
we first performed immunohistochemistry on commer-
cially available tissue microarrays (TMAs) using an anti-
serum specific for the integrin α3 subunit (ITGA3), or the
corresponding preimmune serum from the same rabbit as
a calibration control [33]. Importantly, positive staining for
the α3 subunit is directly reflective of integrin α3β1 expres-
sion, as β1 is the only integrin β subunit with which the α3
subunit dimerizes [3]. Although α3β1 is a cell surface pro-
tein, tumors that express this integrin at high levels often
show cytoplasmic staining of the α3 subunit, presumably
reflecting α3 that has not reached the cell surface or has
been internalized [36,37]. Consistently, α3 staining was ob-
served in the cytoplasm of the tumor cells, as well as in
some of the surrounding endothelial cells.
After anti-α3 immunostaining was calibrated against
background staining obtained with the preimmune
serum (Figure 1A, preimmune column), all samples were
blindly scored for α3 staining intensity on a scale of 0
(no staining) to 3 (high staining) (Figure 1A, anti-α3 col-
umn; see Methods for details). Analysis of a TMA from
Pantomics revealed variable α3β1 expression among
59 independent cases of IDC, of which 6 (10%) showed
no staining, 20 (34%) showed low staining, 19 (32%)
showed medium staining, and 14 (24%) showed high
staining. Examples of variable α3 expression are shown in
Figure 1A (compare preimmune and anti-α3 columns).
Immunostaining of a smaller TMA containing 12 tissues
Figure 2 (See legend on next page.)
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Figure 2 Expression of integrin α3 and COX2 in human IDC (AMC sample set). (A) Immunostaining was performed and analyzed as in
Figure 1. Images show representative scoring intensities (range of 0-3) for anti-α3 or anti-COX2 of adjacent regions from the same tumor, as
indicated. Scale bar, 25 μM. (B) Table depicts co-distribution of like scores for α3 and COX2 among the 68 IDC samples, as in Figure 1. Spearman’s
rank correlation coefficient (rs = 0.59 and p < 0.0001) indicates a significant correlation between α3 and COX2 expression (see Table 2).
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hyperplasia, invasive lobular carcinoma (ILC), apocrine
carcinoma, and IDC revealed similarly variable α3 staining
(data not shown).
We next expanded our analysis to 68 IDC samples
obtained from the tissue bank at the Albany Medical
Center (AMC) Pathology Department, which included
data regarding tumor grade, lymph node status, me-
tastasis, and survival status. Analysis of these AMC sam-
ples revealed similarly variable α3β1 expression, where 6
(9%) showed no staining, 9 (13%) showed low staining, 23
(34%) showed medium staining, and 30 (44%) showed
high staining. Among these tissues, α3 staining was again
detected at varying degrees of intensity in the cytoplasm
of tumor cells, as well as in some stromal cells (Figure 2A,
anti-α3 column).
As shown in Table 1, a statistically significant associ-
ation of α3 staining in the Pantomics array was observed
with tumor grade (p = 0.027; chi-square test for trend)
and HER2 (human epidermal growth factor receptor
2) status (p = 0.013), but not with ER (estrogen receptor)
status, PR (progesterone receptor) status, or tumor stage.
However, similar analysis of the AMC sample set did not
reveal a statistically significant association of α3 staining
with tumor grade or HER2 status, nor with stage, although
in these samples we did detect an association with ER
(p = 0.015) and PR status (p = 0.036). We did not de-
tect an association of α3 expression with tumor me-
tastasis, tumor recurrence, or nodal status. We also did
not observe a statistically significant trend of α3 staining
with triple-negative (i.e., HER2-/ER-/PR-) status (data not
shown), although this sample set was limited to only 13
samples. Thus, while trends were observed within certain
clinicopathologic groupings, these trends did not consist-
ently reach statistical significance in both the Pantomics
TMA and the AMC sample sets.
Analysis of COX2 expression in clinical breast tumor
tissues
Staining with an antiserum specific for COX2 (PTGS2)
was also variable among IDC samples, as shown in Table 1,
and illustrated in Figures 1A and 2A (anti-COX2 col-
umns). Indeed, analysis of the Pantomics TMA revealed
that among the 59 IDC samples, 18 (30%) showed no
staining, 19 (32%) showed low staining, 14 (24%) showed
medium staining, and 8 (14%) showed high staining. Simi-
larly, COX2 staining was variable among the 68 AMC
samples, with 6 (9%) showing no staining, 17 (25%)showing low staining, 23 (34%) showing medium staining,
and 22 (32%) showing high staining.
As shown in Table 1, a statistically significant associ-
ation of COX2 expression was seen with HER2 status
(p = 0.014; chi-square test for trend), but not with tumor
grade, ER status, PR status, or stage. However, similar
analysis of the AMC samples did not reveal a statistically
significant association of COX2 staining with HER2, but
did detect an association with ER (p = 0.001) or PR status
(p = 0.027). Interestingly, despite the differences between
the Pantomics TMA and AMC sample set, the significant
trends observed for COX2 expression within each sample
set were also seen for α3 staining (Table 1), suggesting that
α3 staining and COX2 staining might be correlated
(see below). We did not detect a statistically significant
association of COX2 staining with tumor grade, stage,
tumor metastasis, nodal status, or tumor recurrence.
Expression of COX2 is correlated with expression of α3β1
in human breast cancer
Our previous study showed that integrin α3β1 expres-
sion in MDA-MB-231 human breast cancer cells pro-
motes invasion and tumor growth in part through the
induction of COX2 gene expression [11]. Therefore, we
next wanted to determine whether α3β1 expression is
positively correlated with COX2 expression in human
breast cancer samples. For these analyses, sections from
adjacent regions of the same tissue were scored for cyto-
plasmic staining intensity of either α3 or COX2, using
the 0 to 3 scale described above. Spearman’s rank correl-
ation coefficient analyses were then performed to com-
pare staining intensity between sections and test for a
statistically significant correlation between α3β1 and
COX2 expression patterns.
Initial analysis of TMAs (Pantomics or US Biomax)
showed similar staining of α3 and COX2 in epithelial
cells of both normal breast tissue and breast tumor tis-
sue, as well as in some of the surrounding stromal cells
(data not shown). Analysis of the Pantomics TMA re-
vealed a statistically significant correlation between α3β1
and COX2 expression among IDC samples (Table 2;
Spearman’s rank correlation coefficient rs = 0.49, p < 0.001,
n = 59). Representative images in Figure 1A illustrate the
similar staining patterns and intensities for α3 and COX2
in adjacent regions of the same tumors (compare paired
panels in anti-α3 and anti-COX2 columns). Data regard-
ing the histological grade, tumor stage and hormone
receptor-status were provided by Pantomics, which had
Table 1 Contingency tables for α3 or COX2 scores versus
clinicopathology
α3 scores Cox-2 scores
0 1 2 3 p-value 0 1 2 3 p-value
Pantomics TMA
Histological grade
I (n = 2) 1 0 0 1 0.027* 1 0 1 0 0.64
II (n = 22) 5 6 5 6 6 9 3 4
III (n = 35) 0 14 14 7 11 10 10 4
Stage
Early (n = 47) 4 16 14 13 0.25 13 15 11 8 0.16
Advanced (n = 12) 2 4 5 1 5 4 3 0
HER2
Negative (n = 21) 4 9 6 2 0.013* 10 7 3 1 0.014*
Positive (n = 38) 2 11 13 12 8 12 11 7
ER
Negative (n = 33) 3 13 12 5 0.28 12 11 7 3 0.14
Positive (n = 26) 3 7 7 9 6 8 7 5
PR
Negative (n = 29) 3 11 10 5 0.39 11 10 6 2 0.08
Positive (n = 30) 3 9 9 9 7 9 8 6
AMC samples
Histological grade
I (n = 10) 0 1 2 7 0.34 1 2 3 4 0.39
II (n = 35) 2 4 13 16 2 8 10 15
III (n = 23) 4 4 8 7 3 7 10 3
Stage
Early (n = 44) 2 5 15 22 0.06 5 9 15 15 0.89
Advanced (n = 24) 4 4 8 8 1 8 8 7
HER2
Negative (n = 50) 5 7 16 22 0.64 6 12 15 17 0.59
Positive (n = 18) 1 2 7 8 0 5 8 5
ER
Negative (n = 23) 3 5 10 5 0.015* 5 7 10 2 0.001*
Positive (n = 45) 3 4 13 25 1 11 13 20
PR
Negative (n = 32) 4 6 12 10 0.036* 4 11 10 7 0.027*
Positive (n = 36) 2 3 11 20 2 6 13 15
Metastasis
No (n = 64) 5 8 22 29 0.73 5 17 22 20 0.82
Distant (n = 4) 1 0 1 2 1 0 1 2
Nodal status
0 (n = 32) 2 4 10 16 0.34 4 7 12 9 0.49
1 (n = 36) 4 5 13 14 2 10 11 13
Table 1 Contingency tables for α3 or COX2 scores versus
clinicopathology (Continued)
Tumor recurrence
No (n = 49) 4 7 14 24 0.48 4 9 18 18 0.08
Yes (n = 19) 2 2 9 6 2 8 5 4
The distribution of α3 or COX2 staining intensity scores (range 0-3, see
Methods for details) is shown for various clinicopathologic features. Chi-square
tests for trend were performed on the Pantomics TMA to test for a significant
relationship between α3 expression and tumor grade, disease stage, or
hormone-receptor status. AMC samples were additionally assessed with regard
to metastasis, lymph node status, and tumor recurrence. The same tests were
performed for COX2 expression. *p < 0.05 is considered statistically significant;
all significant values are shown in bold.
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0 to 3 scale. Spearman’s rank correlation coefficient ana-
lysis of each group (i.e., HER2-negative vs. HER2-positive)
revealed that a statistically significant, positive correlation
between α3β1 and COX2 expression was observed irre-
spective of the hormone receptor status, histological
grade, or stage of the cancer (Table 2).
We performed similar analysis of the AMC IDC sam-
ples. However, these tissue sections were considerably lar-
ger than the focal regions provided on the commercial
TMAs. Therefore, we first selected an area of tumor cells
within each tissue section that showed the most intense
cytoplasmic staining with the COX2 antiserum as the
“region-of-interest” (ROI), which was assigned a score
of 0 (background staining) to 3 (intense staining).
Staining intensity for α3 was then scored similarly on a 0
to 3 scale in the corresponding ROI of an adjacent region
from the same tissue. As was seen for the Pantomics
TMA, analysis of the AMC sample set revealed a statisti-
cally significant correlation between α3β1 and COX2 ex-
pression (Table 2; Spearman’s rank correlation coefficient
rs = 0.59, p < 0.0001, n = 68). Figure 2A shows representa-
tive images illustrating this correlation (compare paired
panels), which was observed regardless of ER, PR or nodal
status (Table 2). In addition, this correlation was statisti-
cally significant for HER2-negative, lower grade, and early
stage samples, and it approached significance in advanced
stage tumors (p = 0.05). Taken together, our results indi-
cate that expression of COX2 is positively correlated with
expression of α3β1 in clinical samples of human IDC.
Moreover, this relationship holds regardless of hormone
receptor status, and within tumors of different histological
grade or stage.
Since we recently reported that expression of α3β1 in
breast cancer cells is correlated with enhanced tumor
angiogenesis in a preclinical xenograft model [11], we
also assessed the AMC IDC samples for a relationship
between α3 expression and blood vessel density. Blood
vessel area within tumor sections was determined by
quantification of anti-vWF immunostaining using IPLab
(Scanalytics, Inc.), as we have described [35], then compared
Table 2 Correlation of COX2 and α3 among IDC samples
of different subtype or clinicopathology
rs p-value
Pantomics TMA 0.49 < 0.001*
All samples (n = 59)
Histological grade
I (n = 2) N/D N/D
II (n = 22) 0.61 0.002*
III (n = 35) 0.55 0.001*
Stage
Early n = 47 0.56 < 0.001*
Advanced n = 12 0.72 0.008*
HER2
Negative n = 21 0.82 < 0.001*
Positive n = 38 0.47 0.003*
ER
Negative n = 33 0.6 < 0.001*
Positive n = 26 0.57 0.003*
PR
Negative n = 29 0.67 < 0.001*
Positive n = 30 0.49 0.006*
AMC samples
All samples (n = 68) 0.59 < 0.0001*
Histological grade
I (n = 10) 0.69 0.039*
II (n = 35) 0.53 0.001*
III (n = 23) 0.27 0.22
Stage
Early n = 44 0.54 < 0.001*
Advanced n = 24 0.49 0.05
HER2
Negative n = 50 0.54 < 0.001*
Positive n = 18 0.4 0.1862
ER
Negative n = 23 0.63 0.001*
Positive n = 45 0.34 0.02*
PR
Negative n = 32 0.53 0.002*
Positive n = 36 0.42 0.01*
Metastasis
No (n = 64) 0.49 < 0.001*
Distant (n = 4) 0.63 N/D
Nodal status
0 (n = 32) 0.49 0.005*
1 (n = 36) 0.51 0.002*
Table 2 Correlation of COX2 and α3 among IDC samples
of different subtype or clinicopathology (Continued)
Tumor recurrence
No (n = 49) 0.49 < 0.001*
Yes (n = 19) 0.3 0.21
Spearman’s rank correlation coefficient (rs) tests were performed on the
Pantomics TMA to test for correlation between α3 and COX2 expression within
all samples (n = 59), or within subgroups of various clinicopathologic features
including tumor grade, disease stage, or hormone receptor status. AMC
samples (n = 68) were also assessed together, or within the same subgroups,
as well as with regard to metastasis, lymph node status, and tumor recurrence.
N/D, no data. *p < 0.05 is considered statistically significant; all significant
values are shown in bold.
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0 to 3 (one-way ANOVA). Although differences in blood
vessel density among the groups were not statistically sig-
nificant, interestingly we did observe an overall trend of
elevated blood vessel density with increased expression of
α3 (Figure 3).
Discussion
The current study corroborates earlier findings that in-
tegrin α3β1 is detected in a large proportion of human
breast cancers [12], although its expression levels vary
considerably [38]. Importantly, our findings also identify
a novel, positive correlation between the expression of
α3β1 (assessed by staining for the α3 subunit) and
COX2 in clinical samples of human IDC, thereby valid-
ating the clinical relevance of our earlier report that
α3β1 regulates COX2 expression in a preclinical breast
cancer model [11]. The potential translational impact of
these findings lies in the fact that COX2 is already a well
known promoter of breast cancer progression and tumor
angiogenesis that has been exploited in the clinic as a
therapeutic target [21-23,39]. Importantly, however, COX2
inhibitors often produce severe side effects that include
gastrointestinal complications and increased cardiovascular
risks [24,27-29]. Our current findings support the inhib-
ition of integrin α3β1 as a promising therapeutic strategy,
as this approach may provide an alternative mode of sup-
pressing COX2 without the adverse side effects that have
been associated with direct COX2 inhibitors.
The general concept of targeting integrins to inhibit
cancer progression is already established, and clinical test-
ing of peptide antagonists (e.g., the RGD mimetic cilengi-
tide) and humanized monoclonal antibodies that target
certain integrins is well underway [2,40]. However, most
of these agents are currently directed against integrins that
are expressed on endothelial cells and promote tumor
angiogenesis, such as αvβ3 and αvβ5 [2,41]. In contrast,
strategies to inhibit the functions of tumor cell integrins
are relatively underdeveloped, in part due to a critical need
to identify and validate the most appropriate integrins to
target on particular types of cancer cells. A formidable
Figure 3 Assessment of blood vessel density in human IDC with varying α3 expression (AMC sample set). (A) Representative examples of
anti-vWF immunostaining among tumor samples of varying α3 score, as indicated. Arrowheads point to examples of blood vessels. Scale bar,
250 μM. (B) Graph depicts quantification of blood vessel area (i.e., anti-vWF staining above threshold) among tumor samples of varying α3 expression
score, as indicated. Data are average +/- s.e.m.; sample size is indicated for each bar on the graph.
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expressed by tumor cells varies across different types of
cancer, and different integrin αβ heterodimers have dis-
tinct functions [3]. Indeed, clinical studies have revealed
different expression patterns for individual β1 integrins
in breast cancer, where expression of some integrins
(e.g., α3β1) increases or persists compared with normal
tissue [12], while expression of other integrins (e.g., α2β1)
often decreases [42]. Furthermore, a recent study in a
preclinical model identified α2β1 as a suppressor of
breast cancer metastasis [42], in contrast with the pro-
tumorigenic functions that have been described for other
β1 integrins such as α3β1 and α6β1 [11,43,44], emphasiz-
ing the need to identify individual integrins with cancer-promoting roles that would be appropriate to exploit as
therapeutic targets.
Importantly, the results of our current study, combined
with our previous preclinical study [11], provide support
for α3β1 as a promising therapeutic target on breast can-
cer cells. Indeed, the role that α3β1 plays in promoting
COX2 gene expression extends to other genes with pro-
tumorigenic/pro-metastatic roles [11,45], including MMP-
9 [12,46], suggesting that blocking the gene regulatory
functions of this integrin might suppress multiple tumor
cell functions that drive carcinogenesis. α3β1 has been im-
plicated as a potential marker protein for cells undergoing
enhanced EMT or for cancer cells with aggressive pheno-
types [37], and the transcription factor Ets-1 may play role
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Moreover, studies performed in both genetic models and
xenograft models have revealed important roles for
α3β1 in promoting tumorigenic or metastatic behavior
of breast cancer cells. For example, α3β1 has been shown
to promote malignant growth of basal mammary epithelial
cells through activation of intracellular signaling pathways
that involve FAK, Rac1/PAK1, MAPK and JNK [48]. In
addition, orthotopic implantation of aggressive breast can-
cer cell lines in which α3β1 was suppressed using RNAi
displayed significant reductions in primary tumor growth
[11,15], as well as a dramatic reduction of spontaneous or
experimental metastasis [15], indicating important and
potentially separable roles for this integrin at both early
stages of tumorigenesis and later stages of metastasis.
Despite the above progress in preclinical models, little
is known about the importance of α3β1 within different
breast cancer subtypes, or whether α3β1 expression is cor-
related to clinical diagnostic characteristics such as hor-
mone receptor status, tumor stage, or metastasis. Although
our analysis detected trends of increased α3 expression in
IDC of certain hormone receptor status, these trends did
not reach statistical significance in both the AMC samples
and the commercial TMA, so their significance remains
uncertain. We obtained similarly variable results in our
analysis of COX2 expression across IDC samples of distinct
hormonal status, consistent with varying reports of the rela-
tionship between COX2 and hormone receptor status or
other diagnostic criteria. For example, in one report COX2
activation was associated with ER-negative and HER2-
positive breast cancers, while in another it was positively
associated with ER and PR status [49,50]. We also failed
to detect significant associations of either α3 or COX2 ex-
pression with tumor stage, tumor grade, recurrence, nodal
status, or metastasis. Importantly, however, the positive
correlation that we detected between α3 expression and
COX2 expression was statistically significant within sub-
groups of distinct hormone receptor status, histological
grade, or tumor stage, indicating that this correlation is
not associated with any particular IDC subtype or stage.
These findings suggest that targeting α3β1 to inhibit COX2
expression might be an effective therapeutic strategy for
various forms of IDC that express COX2.
While the potential for α3β1 as a useful therapeutic tar-
get for breast cancer is clear, it is important to note that
some studies have indicated suppressive roles for α3β1 in
certain cancer models, indicating that pro-tumorigenic
functions of this integrin may be context-dependent
[51-53]. Indeed, while shRNA-mediated silencing of α3β1
in breast cancer cells reduced cell invasion in vitro and
tumor growth in vivo [11,15], similar silencing of α3β1 en-
hanced lung metastasis in an in vivo model of prostate
cancer [53]. Moreover, α3β1 expression varied consider-
ably among breast tumors, as shown here and by others[12,38]. Interestingly, results from in vitro and in vivo
models have indicated that some α3β1 functions are ac-
quired by some immortalized/transformed cells [46] or
may be associated with distinct stages of progression
within a cancer type [54], indicating that functions of this
integrin may change during cancer development and pro-
gression. For example, a recent study in a squamous cell
carcinoma model showed that epidermis-specific deletion
of α3β1 (i.e., using a conditional α3-knockout model) led
to reduced skin tumorigenesis, whereas tumors that did
form in these mice progressed more readily to invasive
carcinoma, indicating opposing roles for α3β1 in early and
late stages of skin carcinogenesis [54].
Conclusions
In summary, our finding that expression of integrin α3β1
and COX2 are correlated in human IDC is likely to reflect
an important physiological role for the α3β1-dependent
regulation of COX2 gene expression that we described
previously in cultured breast cancer cells [11,45]. To-
gether, these findings support the concept that targeting
α3β1 specifically on tumor cells may provide an alterna-
tive strategy of suppressing COX2 that circumvents ad-
verse side effects associated with current COX2 inhibitors.
This approach might be broadly applicable to different
breast cancer subtypes, since the correlation between α3
expression and COX2 expression was not associated with
any particular hormone receptor status. Another potential
benefit of this approach stems from the ability of α3β1
to regulate other pro-tumorigenic/pro-metastatic genes
[11,45], which suggests that inhibiting this integrin on tumor
cells might produce the effect of a multi-target approach.
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